Host immunity shapes antibiotic response, but adjunctive immune strategies lack clinical proofImmune system health impacts how well antibiotics fight infections
Frontiers in MedicinePublished October 31, 2026DOI ↗Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Recognize that adjunctive immune strategies lack clinical proof; maintain antibiotics and source control.
This narrative review explores the relationship between host innate immune function and antibiotic activity in immunocompromised patients with resistant bacterial infections. It synthesizes experimental findings suggesting that immune function affects bacterial growth, clearance, and observed antibiotic exposure-response relationships. The review also notes that antibiotic-induced changes in bacterial morphology, microbial-product release, and immune recognition may either promote clearance or contribute to inflammatory injury, depending on pathogen, burden, timing, and host state.
The authors discuss several adjunctive immune-based strategies, including colony-stimulating factors, interferon-gamma, innate agonists, pathogen-specific antibodies, and antibody-antibiotic conjugates. They emphasize that these approaches vary substantially in mechanism and strength of evidence, and that clinical assessment requires demonstration of improved infection outcomes in addition to biological activity.
The review is limited by its narrative format, with no reported systematic search, pooled data, or trial-level detail. No adverse events or safety data are provided. The authors propose a research-oriented framework integrating antibacterial exposure, bacterial phenotype and burden, infection compartment, and host immune function, while maintaining effective antibiotic treatment and source control as foundations of care. They explicitly caution against presenting adjunctive immune strategies as clinically proven or inferring efficacy from mechanistic findings.
How this fits prior evidence
This review extends prior coverage on antimicrobial resistance by focusing on host immunity as a determinant of antibiotic response, a dimension not addressed in earlier items on photosensitizers, resistance gene conjugation, or microbiome stewardship. It aligns with the influenza review's identification of knowledge gaps in secondary bacterial infections, reinforcing that immune status is understudied. Unlike the AMR messaging study, it does not address patient behavior. The proposed framework remains conceptual, and no clinical efficacy data are presented.
When a person has a serious bacterial infection, we usually turn straight to antibiotics. However, research shows that the body's own immune system is a silent partner in this fight. The way your immune system functions can actually change how bacteria grow and how well an antibiotic manages to clear the infection from your body.
This is especially important for people with weakened immune systems. The study highlights that antibiotics can cause changes in the shape of bacteria or the substances they release. Depending on the timing and the type of bacteria, these changes can either help the body clear the infection or cause harmful inflammation.
While there are several ways to try and boost the immune system alongside antibiotics, the evidence for these extra treatments varies a lot. Because this was a narrative review, the findings are based on experimental observations rather than large clinical trials. Doctors still recommend standard antibiotic treatments and source control as the main foundation of care.
What this means for you:
The immune system's activity directly influences how effectively antibiotics can clear bacterial infections.
Common questions
How does the immune system affect antibiotic treatment?
The immune system acts as a partner to antibiotics. Research shows that immune function can influence how bacteria grow and how well they are cleared from the body. This means the effectiveness of an antibiotic can change depending on how well the host's immune system is functioning during the infection.
What happens when antibiotics change the bacteria's shape?
Antibiotics can cause changes in bacterial shape and the products they release. These changes can either help the body clear the infection or cause inflammation. The outcome depends on several factors, including the type of pathogen, the amount of bacteria present, and the timing of the treatment.
Are there extra treatments to boost the immune system?
There are several strategies to support the immune system, such as using specific antibodies or immune-boosting agents. However, the evidence for these extra treatments varies a lot in strength and mechanism. Doctors must look for clear evidence of improved outcomes before using these as additional treatments.
Antimicrobial resistance (AMR) is particularly difficult to manage in immunocompromised hosts, in whom impaired bacterial containment and clearance can coexist with restricted treatment options, altered drug exposure, and anatomically complex infection sites. Susceptibility testing and pharmacokinetic/pharmacodynamic (PK/PD) assessment guide antibiotic treatment, while host defenses help determine whether injured bacteria are cleared. This Review examines the host–antibiotic interface in resistant bacterial infection, with emphasis on how innate immunity contributes to antibacterial activity in immunocompromised populations. We distinguish quantitative and qualitative defects in neutrophils, monocyte hyporesponsiveness, complement impairment, barrier disruption, and combined host deficits, and consider how bacterial burden, infection compartment, and protected intracellular or extracellular populations modify drug–host interactions. Experimental studies show that immune function influences bacterial growth, clearance, and observed antibiotic exposure–response relationships. Antibiotic-induced changes in bacterial morphology, microbial-product release, and immune recognition may promote clearance or inflammatory injury depending on pathogen, burden, timing, and host state. Adjunctive approaches, including colony-stimulating factors, interferon-γ, innate agonists, pathogen-specific antibodies, antibody–antibiotic conjugates, and phage–antibiotic combinations, vary substantially in mechanism and strength of supporting evidence. Clinical assessment of adjunctive strategies requires evidence of improved infection outcomes as well as biological activity. We propose a research-oriented framework integrating antibacterial exposure, bacterial phenotype and burden, infection compartment, and host immune function to guide mechanistic investigation, while retaining effective antibiotic treatment and source control when indicated as the foundations of clinical care.
